Suppr超能文献

小脂肪性 HCC:一种与消融治疗后改善预后相关的影像学变异型。

Small Steatotic HCC: A Radiological Variant Associated With Improved Outcome After Ablation.

机构信息

Department of RadiologySt-Eloi University HospitalMontpellierFrance.

Department of OncologySt-Eloi University HospitalMontpellierFrance.

出版信息

Hepatol Commun. 2020 Dec 31;5(4):689-700. doi: 10.1002/hep4.1661. eCollection 2021 Apr.

Abstract

Percutaneous thermal ablation is a validated treatment option for small hepatocellular carcinoma (HCC). Steatotic HCC can be reliably detected by magnetic resonance imaging. To determine the clinical relevance of this radiological variant, we included 235 patients (cirrhosis in 92.3%, classified Child-Pugh A in 97%) from a prospective database on percutaneous thermal ablation for <3 cm HCC. Among these patients, 52 (22.1%) had at least one steatotic HCC nodule. Nonalcoholic steatohepatitis was more frequent in patients with than without steatotic HCC ( = 0.057), whereas body mass index, diabetes mellitus, liver steatosis, and liver fat content did not differ between groups. Liver disease was less advanced in patients with than without steatotic HCC: lower total bilirubin ( 2.1 µmol/L;  = 0.035), higher albumin (+0.8 g/L;  = 0.035), and lower Model for End-Stage Liver Disease score (-0.8;  = 0.014). Tumor phenotype was less aggressive in patients with steatotic HCC: lower alpha-fetoprotein (AFP) concentration ( = 0.019), less frequent AFP > 100 ng/mL ( = 0.045), and multifocality ( = 0.015). During the follow-up (median: 28.3 months), overall mortality (3.8% vs. 23.5%;  = 0.001) and HCC-specific mortality (0.0% vs. 14.2%;  = 0.002) rates were lower in patients with steatotic HCC. Early (<2 years) recurrence was also less frequent (32.7% vs. 49.2%;  = 0.041). The mean time to intrahepatic distant recurrence (16.4 vs. 9 months,  = 0.006) and the median time to recurrence and recurrence-free survival (32.4 vs. 18.6 months,  = 0.024 and 30.4 vs. 16.4 months,  = 0.018) were longer in patients with steatotic versus nonsteatotic HCC. The 3-year overall survival was 94.4% and 70.9% in steatotic and nonsteatotic HCC ( = 0.008). In multivariate analysis, steatotic HCC (hazard ratio = 0.12;  = 0.039) and AFP (HR=1.002;  < 0.001) independently predicted overall survival. Small steatotic HCC detected by magnetic resonance imaging is associated with a less aggressive tumor phenotype. In patients with such radiological variant, percutaneous thermal ablation results in improved outcome.

摘要

经皮热消融是治疗小肝细胞癌(HCC)的一种有效治疗选择。磁共振成像可可靠地检测出脂肪变性 HCC。为了确定这种影像学变异的临床相关性,我们纳入了来自经皮热消融治疗<3cm HCC的前瞻性数据库中的 235 名患者(92.3%为肝硬化,97%为 Child-Pugh A)。在这些患者中,52 名(22.1%)至少有一个脂肪变性 HCC 结节。与无脂肪变性 HCC 患者相比,非酒精性脂肪性肝炎在有脂肪变性 HCC 患者中更为常见(=0.057),而体重指数、糖尿病、肝脂肪变性和肝脂肪含量在两组之间没有差异。与无脂肪变性 HCC 患者相比,脂肪变性 HCC 患者的肝病进展程度较低:总胆红素较低( 2.1μmol/L;=0.035),白蛋白水平较高(+0.8g/L;=0.035),终末期肝病模型评分较低(-0.8;=0.014)。与无脂肪变性 HCC 患者相比,脂肪变性 HCC 患者的肿瘤表型侵袭性较低:甲胎蛋白(AFP)浓度较低(=0.019),AFP>100ng/mL 的频率较低(=0.045),多灶性较低(=0.015)。在随访期间(中位数:28.3 个月),脂肪变性 HCC 患者的总死亡率(3.8% vs. 23.5%;=0.001)和 HCC 特异性死亡率(0.0% vs. 14.2%;=0.002)较低。早期(<2 年)复发也较少(32.7% vs. 49.2%;=0.041)。肝内远处复发的平均时间(16.4 与 9 个月,=0.006)和复发及无复发生存时间的中位数(32.4 与 18.6 个月,=0.024 和 30.4 与 16.4 个月,=0.018)在脂肪变性 HCC 患者中更长。脂肪变性 HCC 和非脂肪变性 HCC 的 3 年总生存率分别为 94.4%和 70.9%(=0.008)。多变量分析显示,脂肪变性 HCC(风险比=0.12;=0.039)和 AFP(HR=1.002;<0.001)独立预测总生存率。磁共振成像检测到的小脂肪变性 HCC 与侵袭性较低的肿瘤表型相关。对于这种影像学变异的患者,经皮热消融治疗可改善预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b93e/8034567/13f3e85cb11a/HEP4-5-689-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验